These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 33074119)
1. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers. Amin NH; Elsaadi MT; Zaki SS; Abdel-Rahman HM Bioorg Chem; 2020 Dec; 105():104358. PubMed ID: 33074119 [TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
3. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study. AboulWafa OM; Daabees HMG; Badawi WA Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112 [TBL] [Abstract][Full Text] [Related]
4. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study. El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114 [TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents. Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers. El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290 [TBL] [Abstract][Full Text] [Related]
9. Development of pyridazine derivatives as potential EGFR inhibitors and apoptosis inducers: Design, synthesis, anticancer evaluation, and molecular modeling studies. Ahmed MF; Santali EY; Mohi El-Deen EM; Naguib IA; El-Haggar R Bioorg Chem; 2021 Jan; 106():104473. PubMed ID: 33243490 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors. Olgen S; Kaleli SNB; Karaca BT; Demirel UU; Bristow HK Curr Med Chem; 2024; 31(24):3798-3817. PubMed ID: 37365789 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors. Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
14. New 6-nitro-4-substituted quinazoline derivatives targeting epidermal growth factor receptor: design, synthesis and Farag AB; Othman AH; El-Ashrey MK; Abbas SE; Elwaie TA Future Med Chem; 2024; 16(19):2025-2041. PubMed ID: 39230501 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy. Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494 [TBL] [Abstract][Full Text] [Related]
16. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors. Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Shaheen MA; El-Emam AA; El-Gohary NS Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080 [TBL] [Abstract][Full Text] [Related]
18. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]